In short
This article discusses ongoing clinical trials investigating the use of AZD0486, a human IgG4 kappa monoclonal antibody targeting CD3 and CD19, in patients with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL). The trials aim to evaluate the safety, tolerability, and effectiveness of this novel treatment approach in adolescents and adults with this challenging form of leukemia.
At a glance
- Drug Name
- AZD0486 (Human IgG4 Kappa Monoclonal Antibody Against CD3 and CD19)
- Trial Phase
- Phase 1/2
- Condition
- Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia (B-ALL)
- Age Range
- 12-80 years (varies by trial part)
- Administration
- Intravenous infusion
- Primary Objectives
- Safety, tolerability, and efficacy assessment
- Key Endpoints
- Dose-limiting toxicities, overall response rate, duration of response, survival measures
- Exclusion Criteria
- Active CNS involvement, isolated extramedullary disease, testicular leukemia, certain prior therapies
What is AZD0486?
AZD0486 is a new medication being studied for the treatment of a specific type of blood cancer. Its scientific name is human IgG4 kappa monoclonal antibody against CD3 and CD19. This means it's a specially designed protein that can target two specific molecules (CD3 and CD19) found on certain blood cells.
The medication is given as a solution for infusion, which means it's administered directly into the bloodstream through an intravenous (IV) line.
Target Condition: B-Cell Acute Lymphoblastic Leukemia
AZD0486 is being studied to treat B-Cell Acute Lymphoblastic Leukemia (B-ALL). This is a type of blood cancer that affects a specific kind of white blood cell called B-lymphocytes. In B-ALL, these cells grow out of control and don't mature properly, which can crowd out healthy blood cells.
The study is specifically looking at patients with relapsed or refractory B-ALL. This means:
- Relapsed: The cancer has come back after initial treatment
- Refractory: The cancer hasn't responded well to previous treatments
How AZD0486 Works
AZD0486 is designed to work in a unique way:
- It targets CD19, a molecule found on B-cells (including cancerous B-ALL cells)
- It also targets CD3, a molecule found on T-cells (another type of immune cell)
- By binding to both, it may help direct the patient's own T-cells to attack and kill the cancerous B-cells
This approach is known as a bispecific antibody because it targets two different molecules at once.
Clinical Trial Overview
AZD0486 is currently being studied in a clinical trial called SYRUS (also known by the number D7405C00001). This is a Phase 1/2 study, which means it's still in the early stages of testing in humans.
The trial is divided into three parts:
- Part A (Phase 1a): Dose escalation - finding the right dose
- Part B (Phase 1b): Dose optimization - fine-tuning the dose
- Part C (Phase 2): Expansion - testing the chosen dose in more patients
Who Can Participate in the Trial?
The trial is looking for patients with specific characteristics, including:
- Age: 16-80 years old for Part A, 12-80 years old for Parts B and C
- Diagnosed with CD19+ B-cell Acute Lymphoblastic Leukemia
- Cancer that has relapsed or is refractory after at least 2 prior therapies (or 1 prior therapy if no standard treatment is available)
- Relatively good overall health (measured by specific scoring systems)
There are also certain conditions that would prevent someone from participating, such as active cancer in the central nervous system or certain other medical conditions.
Trial Objectives
The main goals of this clinical trial are:
- To assess if AZD0486 is safe and well-tolerated by patients
- To evaluate how effective AZD0486 is in treating relapsed or refractory B-ALL
- To understand how the drug moves through and is processed by the body (pharmacokinetics)
- To check if patients develop an immune response to the drug (immunogenicity)
Safety and Efficacy Measures
The researchers will be looking at several factors to determine if AZD0486 is safe and effective:
- Safety: They'll monitor for any side effects or adverse events
- Overall Response Rate (ORR): How many patients see their cancer improve or disappear
- Duration of Response (DoR): How long the improvement lasts
- Event-free Survival (EFS): How long patients live without their disease getting worse
- Overall Survival (OS): How long patients live overall
- Minimal Residual Disease (MRD): Looking for very small amounts of cancer cells that might remain after treatment
Potential Benefits of AZD0486
While it's important to remember that AZD0486 is still in the testing phase, there are several potential benefits that researchers hope to see:
- A new treatment option for patients who haven't responded well to other therapies
- Possibly more targeted treatment with fewer side effects than traditional chemotherapy
- Potential to achieve deeper remissions (measured by MRD negativity)
- May help some patients become eligible for stem cell transplant, which could offer a chance for long-term remission
It's crucial to note that more research is needed to confirm these potential benefits, and patients should discuss all treatment options with their healthcare team.